Markets
Youngevity International, Inc. Provides Business Update in Open Letter to Shareholders
- B. Riley Financial Closes Upsized $65 Million Common Stock Offering Including Full Exercise of Underwriter Option - January 18, 2021
- SHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations - January 18, 2021
- Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering - January 18, 2021
Markets
B. Riley Financial Closes Upsized $65 Million Common Stock Offering Including Full Exercise of Underwriter Option
B. Riley Financial, Inc. (NASDAQ: RILY) (“B. Riley” or the “Company”) today announced that it has closed an underwritten registered public offering of 1,413,045 shares of its common stock, which included 184,310 shares issued in connection with the underwriter’s option to purchase additional shares, at a price to the public of $46.00 per share (the “Offering”), for gross proceeds of approximately $65.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. Certain of the Company’s officers, directors and employees purchased an aggregate of 149,670 shares in the offering at the public offering price.
The offering resulted in net proceeds of approximately $61.4 million after deducting underwriting discounts and commissions, but before expenses. The Company expects to use the net proceeds of this offering for general corporate purposes, including funding future acquisitions and investments, making capital expenditures and funding working capital.
B. Riley Securities, Inc. acted as sole book-running manager for the offering.
The NBD Group acted as legal counsel to the Company. Duane Morris LLP acted as legal counsel to the underwriter.
The shares of common stock were offered under the Company’s shelf registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission (“SEC”) on February 24, 2020. The offering was made only by means of a prospectus supplement and accompanying base prospectus.
Copies of the prospectus supplement and the accompanying base prospectus may be obtained on the SEC’s website at www.sec.gov, or by contacting B. Riley Securities by telephone at (703) 312-9580, or by emailing prospectuses@brileyfin.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would not be permitted.
About B. Riley Financial, Inc. (NASDAQ: RILY)
B. Riley Financial, Inc. provides collaborative financial services solutions tailored to fit the capital raising, business, operational, and financial advisory needs of its clients and partners. B. Riley operates through several subsidiaries which offer a diverse range of complementary end-to-end capabilities spanning investment banking and institutional brokerage, private wealth and investment management, corporate advisory, restructuring, due diligence, forensic accounting, litigation support, appraisal and valuation, and auction and liquidation services. Certain registered affiliates of B. Riley originate and underwrite senior secured loans for asset-rich companies. B. Riley also makes proprietary investments in companies and assets with attractive return profiles.
Forward-Looking Statements
Statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of the date of this press release. Such forward looking statements include, but are not limited to, statements regarding the terms and conditions and timing of the common stock offering and the intended use of proceeds. Because these forward-looking statements involve known and unknown risks and uncertainties, there are important factors that could cause actual results, events or developments to differ materially from those expressed or implied by these forward-looking statements. Factors that could cause actual results to differ include (without limitation) the possibility that the common stock offering will not be consummated at the expected time, on the expected terms, or at all; and the Company’s financial performance; and those risks described from time to time in B. Riley’s periodic filings with the SEC, including, without limitation, the risks described in B. Riley’s Annual Report on Form 10-K for the year ended December 31, 2019 under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Additional information is also set forth in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and B. Riley undertakes no duty to update this information.
|
Contacts |
|
|
Investors |
Media |
|
Investor Relations |
Jo Anne McCusker |
|
(310) 966-1444 |
(646) 885-5425 |
SOURCE B. Riley Financial
Related Links
This article appeared first on here.
- B. Riley Financial Closes Upsized $65 Million Common Stock Offering Including Full Exercise of Underwriter Option - January 18, 2021
- SHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations - January 18, 2021
- Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering - January 18, 2021
Markets
SHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
Experience Investment Corp. (NASDAQ: EXPC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Experience Investment Corp. (NASDAQ: EXPC) in connection with the company’s proposed merger with privately-held Blade Urban Air Mobility, Inc. (“Blade”). Under the terms of the merger agreement, EXPC will acquire Blade through a reverse merger that will result in Blade becoming a public company traded on the NASDAQ. The estimated post-transaction equity value of the combined company is approximately $825 million. If you own EXPC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/EXPC/
CIIG Merger Corp. (NASDAQ: CIIC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CIIG Merger Corp. (NASDAQ: CIIC) in connection with the company’s proposed merger with privately-held Arrival S.à r.l. (“Arrival”). Under the terms of the merger agreement, CIIC will acquire Arrival through a reverse merger that will result in Arrival becoming a public company traded on the NASDAQ. The estimated post-transaction equity value of the combined company is approximately $5.4 billion. If you own CIIC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/CIIG/
Altimar Acquisition Corp. (NYSE: ATAC)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Altimar Acquisition Corp. (NYSE: ATAC) in connection with the company’s proposed merger with privately-held Owl Rock Capital Group (“Owl Rock”) and Dyal Capital Partners (“Dyal Capital”). ATAC will combine with Owl Rock and Dyal Capital via a reverse merger to create a single publicly-traded company. If you own ATAC shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/ATAC/
Longview Acquisition Corp. (NYSE: LGVW)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Longview Acquisition Corp. (NYSE: LGVW) in connection with the company’s proposed merger with privately-held Butterfly Network, Inc. (“Butterfly Network”). Under the terms of the merger agreement, LGVW will acquire Butterfly Network through a reverse merger that will result in Butterfly Network becoming a publicly-traded company. If you own LGVW shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/LGVW/
SOURCE WeissLaw LLP
Related Links
This article appeared first on here.
- B. Riley Financial Closes Upsized $65 Million Common Stock Offering Including Full Exercise of Underwriter Option - January 18, 2021
- SHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations - January 18, 2021
- Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering - January 18, 2021
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced the closing on January 14, 2021, of its $10 million registered direct offering consisting of the purchase and sale of 2,221,358 shares of Enveric’s common stock and common stock equivalents, at a purchase price of $4.5018 per share. Also, Enveric has issued to the investors unregistered warrants to acquire 1,666,019 shares of Common Stock at $4.9519 per share, exercisable immediately and terminating five years after the date of issuance.
The net proceeds to Enveric from the offering after deducting financial advisory fees and other costs and expenses were approximately $9 million. Enveric intends to use the net proceeds from this offering for working capital and general corporate purposes.
Palladium Capital Group, LLC acted as a financial advisor to the issuer.
The shares of common stock (but not the warrants or the shares of common stock underlying the warrants) were offered by Enveric pursuant to a “shelf” registration statement on Form S-3 (File No. 333-233260) previously filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2019, and declared effective by the SEC on November 19, 2019. The offering of the securities (other than the warrants and the shares of common stock underlying the warrants) was made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The final prospectus supplement and accompanying prospectus relating to the shares of common stock being offered were filed with the SEC. Electronic copies of the final prospectus supplement and accompanying prospectus can be obtained on the SEC’s website at http://www.sec.gov.
The warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Enveric has agreed to register the shares of common stock issuable upon exercise of the warrants for resale pursuant to a customary registration rights agreement.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Enveric Biosciences
Enveric Biosciences is a patient-first biotechnology company developing rigorously tested, novel, cannabinoid medicines to improve quality of life for cancer patients. Initial indications include radiodermatitis, a common and often severe side effect of radiation therapy, and chemotherapy-induced neuropathy. For more information, please visit https://www.enveric.com/.
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans”, ” expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the impact of the novel coronavirus (COVID-19) on Enveric’s ongoing and planned clinical trials; the geographic, social and economic impact of COVID-19 on Enveric’s ability to conduct its business and raise capital in the future when needed; delays in planned clinical trials; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; Enveric’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to Enveric’s products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s registration statement on Form S-4 filed on May 28, 2020, as amended. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
212.896.1254 / 212.896.1267
EnvericBio@kcsa.com
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
EnvericBio@kcsa.com
SOURCE Enveric Biosciences
Related Links
This article appeared first on here.
- B. Riley Financial Closes Upsized $65 Million Common Stock Offering Including Full Exercise of Underwriter Option - January 18, 2021
- SHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations - January 18, 2021
- Enveric Biosciences Inc. Announces Closing of $10 Million Registered Direct Offering - January 18, 2021
-
BenzingaEditorial4 days agoEurope and EVs- A Blossoming Relationship
-
BenzingaEditorial4 days agoThe EV Industry Is Worth More Than The Traditional Automakers
-
Markets4 days agoBig Oil Missed This, Now It Could Be Worth Billions
-
Markets4 days agoLuokung Announces Statement on Being Included in the Relevant List by the U.S Department of Defense
-
BenzingaPRs4 days agoIdeanomics Announces MEG December and Q4 Sales Activity
-
Markets4 days agoFuture FinTech Group Inc. Announces the Closing of $15 Million Registered Direct Offering
-
Markets16 hours agoSHAREHOLDER ALERT: WeissLaw LLP Reminds EXPC, CIIC, ATAC, and LGVW Shareholders About Its Ongoing Investigations
-
Markets4 days agoLantern Pharma Announces Pricing of $60 Million Public Offering
